Arrowhead 制药

US · ARWR #1569 按市值排名上市于 1970

55.90 -2.60 -4.44%

实时 - 追踪5344个代码 - 心跳于196秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量减少了3家。
机构持股总比例下降了0.2个百分点。

机构持股

机构持股比例: 87.20% -0.19pp
机构数量: 584 -3
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund59.19%

Hedge Fund16.73%

Public Company4.32%

Individual/Insider3.32%

Sovereign Wealth Fund2.76%

Private Company1.60%

VC/PE Fund1.22%

Government Pension Fund1.00%

Insurance Company0.20%

Other9.67%

主要股东截至 2026-06-30

BlackRock 10.50% · 14.83M 股

Avoro Capital Advisors LLC 8.04% · 11.36M 股

FMR 5.69% · 8.03M 股

Vanguard Capital Management, LLC 4.96% · 7.01M 股

Vanguard Portfolio Management, LLC 4.50% · 6.35M 股

State Street Global Advisors 4.03% · 5.69M 股

Norges Bank Investment Management 2.76% · 3.90M 股

Christopher Anzalone 2.69% · 3.79M 股

Geode Capital Management, LLC 2.50% · 3.53M 股

Fred Alger Management, LLC 2.34% · 3.30M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 12次买入 · 37次卖出

姓名	职务	持股比例
Christopher Anzalone	Chief Executive Officer	2.69%
Patrick O'Brien	COO, General Counsel & Secretary	0.24%
James Hamilton	Chief of Discovery & Translational Medicine	0.16%
Michael Perry	Lead Independent Director	0.07%
Mauro Ferrari	Independent Director	0.04%
William Waddill	Independent Director	0.03%
Hongbo Lu	Independent Director	0.03%
Adeoye Olukotun	Independent Director	0.02%
Victoria Vakiener	Independent Director	0.02%
Daniel Apel	Chief Financial Officer	0.01%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-08-17	Adeoye Olukotun	Independent Director	Open Market Disposition	-2,000	$86.96
2026-08-17	Michael Perry	Lead Independent Director	Open Market Disposition	-11,600	$87.30
2026-06-14	Matthew Cohen	Director	Other Acquisition	+11,882	--
2026-05-11	Hongbo Lu	Independent Director	Open Market Disposition	-2,970	$76.88
2026-05-11	Hongbo Lu	Independent Director	Intent to Sell (Form 144)	-315,202	--
2026-04-22	James Hamilton	Chief of Discovery & Translational Medicine	Automatic Disposition	-10,000	$75.00
2026-04-22	James Hamilton	Chief of Discovery & Translational Medicine	Intent to Sell (Form 144)	-10,000	--
2026-04-21	Daniel Apel	Chief Financial Officer	Automatic Disposition	-13,095	$70.11–71.92
2026-04-21	Daniel Apel	Chief Financial Officer	Intent to Sell (Form 144)	-13,095	--
2026-03-04	James Hamilton	Chief of Discovery & Translational Medicine	Automatic Disposition	-10,000	$64.19
2026-01-05	Daniel Apel	Chief Financial Officer	Other Acquisition	+75,000	--
2026-01-05	James Hamilton	Chief of Discovery & Translational Medicine	Other Acquisition	+75,000	--
2026-01-05	Patrick O'Brien	COO, General Counsel & Secretary	Other Acquisition	+75,000	--
2026-01-05	Patrick O'Brien	COO, General Counsel & Secretary	Other Disposition	-2,500	--
2026-01-04	James Hamilton	Chief of Discovery & Translational Medicine	Automatic Disposition	-40,164	$61.24–68.00
2026-01-04	James Hamilton	Chief of Discovery & Translational Medicine	Intent to Sell (Form 144)	-40,164	$63.10
2026-01-04	Patrick O'Brien	COO, General Counsel & Secretary	Automatic Disposition	-49,493	$61.12–68.00
2026-01-01	Christopher Anzalone	Chief Executive Officer	Automatic Disposition	-13,187	$65.88–66.39
2025-12-30	Patrick O'Brien	COO, General Counsel & Secretary	Other Disposition	-2,800	--
2025-12-28	Christopher Anzalone	Chief Executive Officer	Derivative Exercise and Sale	-51,726	$6.15–69.33

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。